Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
AssigneeIpsen Pharma S.A.S.
InventorsGiovanni Tulipano, Andrea Giustina, Zheng Xin Dong, Michael DeWitt Culler
Life of this patent
Estimating the term…
Abstract
A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
Claims20
A method to ameliorate the catabolic effects of excess glucocorticoids in a child in need of such treatment comprising administering to said child a therapeutically effective amount of a ghrelin agonist, wherein said excess glucocorticoids are the result of the long term administration of dexamethasone.
A method for allowing the long term administration of therapeutic doses of dexamethasone to a child to treat a disease or condition, comprising alleviating the catabolic effects of the administration of said long term therapeutic doses of dexamethasone by the administration of a ghrelin agonist.
Dependencies are inferred from the claim text.